Preemptive interleukin-6 blockade in patients with COVID-19

Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillén, Lucía, Padilla, Sergio, Fernández, Marta, Agulló, Vanesa, García, José Alberto, Telenti, Guillermo, García-Abellán, Javier, Botella, Ángela, Gutiérrez, Félix, Masiá, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545205/
https://www.ncbi.nlm.nih.gov/pubmed/33033405
http://dx.doi.org/10.1038/s41598-020-74001-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545205/
https://www.ncbi.nlm.nih.gov/pubmed/33033405
http://dx.doi.org/10.1038/s41598-020-74001-3

Ejemplares similares